Brains for Change

Recently, a link to an article by the Harvard Gazette on AI usage appeared on my LinkedIn feed. It made me pause over something far less visible than a clinical breakthrough, but just as consequential: the question of who is responsible when artificial intelligence begins to shape medical decisions. As AI tools move rapidly into healthcare—assisting with diagnoses, predicting patient outcomes, and even guiding treatment plans—the article raises a deceptively simple question: who should regulate it?

At first glance, the momentum is exciting. AI systems have demonstrated the ability to analyze vast datasets, identify patterns beyond human perception, and potentially improve both the speed and accuracy of care. In areas like radiology and predictive medicine, these tools could help detect disease earlier and allocate resources more efficiently. But the pace of innovation is outstripping the frameworks designed to oversee it. Unlike traditional medical technologies, AI systems are dynamic; they evolve with new data, making them harder to evaluate, standardize, and hold accountable.

Image source: Forbes

In a field where decisions can carry life-altering consequences, uncertainty around responsibility becomes especially significant. If an algorithm makes an error, is accountability assigned to the developer, the physician, the institution, or the system itself? The article highlights that existing regulatory bodies, including the FDA, are still adapting to these questions, working to balance the need for innovation with the imperative of patient safety.

Policy conversations about healthcare often focus on access, cost, and delivery. Those remain critical. Articles like this, however, point to an emerging layer of complexity: that the future of medicine will not only depend on new technologies, but on how thoughtfully we govern them. The challenge is not simply to build more powerful systems, but to ensure they are integrated into care with clarity, accountability, and trust.